The nanoTherics Board combines strong, world-leading scientific acumen, with proven entrepreneurial and industrial expertise. The team has experience across life science and pharmaceutical industries, with track records in building successful start-up ventures from academic research.
Chief Executive Officer
Carl has over 27 years of success in the life sciences commercial field. He has direct experience of developing sales and distribution channels across a range of disciplines within the global life sciences sector coupled with significant experience of implementing market penetration strategies for new products and technologies. His prior position was with Thalesnano where he was responsible as Global Head of Sales for developing business with a disruptively innovative instrumentation and consumables range. Previous roles include a variety of senior positions including Sales Director Europe, Middle East and Africa for Thermo Biosciences where he managed both direct and distribution channels, Managing Director at Affinity Sensors, an evanescent wave optical biosensor company, VP Sales and Marketing USA for Labsystems and various Business Development and Business Unit management roles in the life sciences instrumentation/consumables sector.
Dr Linda E Cammish MBA
Commercial / Operations Consultant and Director
Linda has 29+ years experience in the life science sector, with 20+ years of this being in a commercial environment. Her strong life science background includes a Ph.D. from Cambridge University (with research conducted at the Laboratory of Molecular Biology in Cambridge) and her business education includes an MBA from Henley Business College. She also has considerable practical, hands-on experience in growing businesses in the high technology life science sector involving products and services (including reagents, hardware, software as well as drug discovery services and technology access programmes) for the academic, pharmaceutical and biotechnology markets. She combines this technical and business education with extensive practical experience in senior business development, sales and marketing roles in companies including Millipore, PerSeptive Biosystems, Applied Biosystems and Abcam.
Dr Mark Payton MBA
Non-Executive Director representing Mercia; Acting Chairman
Mark is the fund principal for the Mercia Technology Seed Fund. Mark has a PhD from King’s College (University of London) and an MBA from Warwick Business School. Prior to joining the fund, Mark was a research fellow at the Department of Pharmacology (University of Oxford), played leading roles within Isis Innovation (the technology transfer arm of the University of Oxford, ranked as the premier technology transfer office in the UK) and was VP Corporate Development at Oxxon Therapeutics Inc (before its sale to Oxford BioMedica Plc). Mark benefits from in excess of 15 years experience from the commercialisation of life science opportunities in the biotech, niche pharma, medtech and diagnostics fields.
Andrew is a Genetics graduate who spent several years in sales and managerial roles within the biological software industry before becoming a founding partner and CEO of Improvision Ltd in 1990. Under his leadership, Improvision developed proprietary life science imaging products and by a process of innovation, market focus and identifying future opportunities, Andrew implemented plans that established Improvision as a world leader in the international bio-imaging market. In 2007 Improvision was sold to the PerkinElmer group, a $1.5bn turnover company. A successful entrepreneur and business manager, Andrew brings a strong commercial background to nanoTherics together with extensive knowledge of the European and US software markets, making him a valuable addition to the team.
Professor Jon Dobson
Jon holds a personal chair in Biophysics and Biomedical Engineering at the Institute for Science & Technology in Medicine (ISTM), Keele University and an Eminent Scholar Visiting Professorship at the Department of Materials Science & Engineering, University of Florida. He has a B.Sc. and M.Sc. from the University of Florida and a Ph.D. from the Swiss Federal Institute of Technology (ETH-Zurich, 1991). In 2004, Professor Dobson became a Royal Society Wolfson Research Merit Fellow and was elected as Fellow of the Royal Society of Medicine and Fellow of the Institute for Nanotechnology in 2007. He has more than 150 peer-reviewed publications and has been an invited speaker at more than 25 institutes & scientific meetings, including the recent Royal Society of Medicine / US Food & Drug Administration Conference on Gene Therapy: State of the Art. Since 2003, he has authored 17 invited reviews and articles for journals such as Nature Nanotechnology, Journal of Physics D and Gene Therapy.
Professor Dobson was the recipient of a UK Medical Research Council Milstein Award in 2008 and co-recipient of a Wellcome Trust Showcase Award in 2002. He is on the editorial board of seven journals, including IEEE Transactions on NanoBioscience and Recent Patents on DNA and Gene Sequences and is a member of the EPSRC Peer Review College.